Cargando…
Xeno-free pre-vascularized spheroids for therapeutic applications
Spheroid culture has gained increasing popularity, arising as a promising tool for regenerative medicine applications. Importantly, spheroids may present advantages over single-cell suspensions in cell-based therapies (CT). Unfortunately, most growth media used for spheroid culture contain animal or...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762877/ https://www.ncbi.nlm.nih.gov/pubmed/29321569 http://dx.doi.org/10.1038/s41598-017-18431-6 |
_version_ | 1783291781501157376 |
---|---|
author | Bauman, E. Feijão, T. Carvalho, D. T. O. Granja, P. L. Barrias, C. C. |
author_facet | Bauman, E. Feijão, T. Carvalho, D. T. O. Granja, P. L. Barrias, C. C. |
author_sort | Bauman, E. |
collection | PubMed |
description | Spheroid culture has gained increasing popularity, arising as a promising tool for regenerative medicine applications. Importantly, spheroids may present advantages over single-cell suspensions in cell-based therapies (CT). Unfortunately, most growth media used for spheroid culture contain animal origin-components, such as fetal bovine serum (FBS). The presence of FBS compromises the safety of CT and presents economic and ethical constraints. SCC (supplement for cell culture) is a novel xeno-free (XF) industrial cell culture supplement, derived from well-controlled pooled human plasma and processed under good manufacturing practice rules. Here, we developed a XF SCC-based formulation for 2D-culture of outgrowth endothelial cells (OEC), and then used it for generating co-culture spheroids of OEC and mesenchymal stem cells (MSC). XF MSC-OEC spheroids were characterized in detail and compared to spheroids cultured in FBS-supplemented medium. XF spheroids presented comparable integrity, size and morphology as the reference culture. The use of both media resulted in spheroids with similar structure, abundant extracellular matrix deposition and specific patterns of OEC distribution and organization. Notably, XF spheroids presented significantly enhanced angiogenic potential, both in vitro (fibrin sprouting assay) and in vivo (CAM assay). These findings are particularly promising in the context of potential therapeutic applications. |
format | Online Article Text |
id | pubmed-5762877 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-57628772018-01-17 Xeno-free pre-vascularized spheroids for therapeutic applications Bauman, E. Feijão, T. Carvalho, D. T. O. Granja, P. L. Barrias, C. C. Sci Rep Article Spheroid culture has gained increasing popularity, arising as a promising tool for regenerative medicine applications. Importantly, spheroids may present advantages over single-cell suspensions in cell-based therapies (CT). Unfortunately, most growth media used for spheroid culture contain animal origin-components, such as fetal bovine serum (FBS). The presence of FBS compromises the safety of CT and presents economic and ethical constraints. SCC (supplement for cell culture) is a novel xeno-free (XF) industrial cell culture supplement, derived from well-controlled pooled human plasma and processed under good manufacturing practice rules. Here, we developed a XF SCC-based formulation for 2D-culture of outgrowth endothelial cells (OEC), and then used it for generating co-culture spheroids of OEC and mesenchymal stem cells (MSC). XF MSC-OEC spheroids were characterized in detail and compared to spheroids cultured in FBS-supplemented medium. XF spheroids presented comparable integrity, size and morphology as the reference culture. The use of both media resulted in spheroids with similar structure, abundant extracellular matrix deposition and specific patterns of OEC distribution and organization. Notably, XF spheroids presented significantly enhanced angiogenic potential, both in vitro (fibrin sprouting assay) and in vivo (CAM assay). These findings are particularly promising in the context of potential therapeutic applications. Nature Publishing Group UK 2018-01-10 /pmc/articles/PMC5762877/ /pubmed/29321569 http://dx.doi.org/10.1038/s41598-017-18431-6 Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Bauman, E. Feijão, T. Carvalho, D. T. O. Granja, P. L. Barrias, C. C. Xeno-free pre-vascularized spheroids for therapeutic applications |
title | Xeno-free pre-vascularized spheroids for therapeutic applications |
title_full | Xeno-free pre-vascularized spheroids for therapeutic applications |
title_fullStr | Xeno-free pre-vascularized spheroids for therapeutic applications |
title_full_unstemmed | Xeno-free pre-vascularized spheroids for therapeutic applications |
title_short | Xeno-free pre-vascularized spheroids for therapeutic applications |
title_sort | xeno-free pre-vascularized spheroids for therapeutic applications |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762877/ https://www.ncbi.nlm.nih.gov/pubmed/29321569 http://dx.doi.org/10.1038/s41598-017-18431-6 |
work_keys_str_mv | AT baumane xenofreeprevascularizedspheroidsfortherapeuticapplications AT feijaot xenofreeprevascularizedspheroidsfortherapeuticapplications AT carvalhodto xenofreeprevascularizedspheroidsfortherapeuticapplications AT granjapl xenofreeprevascularizedspheroidsfortherapeuticapplications AT barriascc xenofreeprevascularizedspheroidsfortherapeuticapplications |